Skip to main content
TipRanks
Go Ultimate75% OFF

EyePoint Pharmaceuticals (PV3B) Stock Price & Analysis

1 Followers

PV3B Stock Chart & Stats

€0.25-€0.03(-9.35%)
At close: 5:30 PM GMT+1
€2.5€5Aug 25Sep 8Sep 21Oct 6Oct 19
Day’s Range
EUR 0.25 - EUR 0.25
52-Week Range
EUR 0.25 - EUR 16.13
Previous Close
EUR 0.28
Volume
N/A
Average Volume (3M)
58
Market Cap
EUR 28.21M
Enterprise Value
EUR 195.37M
Total Cash (Recent Filing)
EUR 118.21M
Total Debt (Recent Filing)
EUR 19.12M
Price to Earnings (P/E)
―
Beta
1.57
Next Earnings
Mar 04, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

DME Clinical Signal

Positive Phase II DME results provide a differentiated clinical foundation for the company’s central program. Equivalent vision improvement, better anatomical measures, and fewer supplemental injections could support adoption if these benefits are reproduced in pivotal trials.

Sustained-Release Platform

The sustained-release delivery approach addresses treatment burden, a persistent challenge in retinal disease care. Six-month redosing and practical administration could improve adherence and physician appeal, while the multi-mechanism profile may support differentiation across targeted indications.

Cost Structure Reset

The restructuring aligns operating expenses with a narrower DME strategy and should materially reduce the recurring cash cost of development. These savings can extend financial flexibility, concentrate resources on the lead program, and improve execution discipline over the next several quarters.

Bears Say

Wet AMD Phase III Failure

Failure of both pivotal wet AMD trials removed a major development pathway and led to program discontinuation. This narrows the company’s clinical portfolio, eliminates near-term regulatory optionality in that indication, and leaves DME as the principal driver of future value.

Persistent Cash Burn

Deeply negative operating and free cash flow indicate that the business is not currently self-funding its development activities. Continued cash consumption can require external financing or partnerships, potentially limiting strategic flexibility and increasing execution pressure around clinical milestones.

Runway And Financing Risk

The stated runway does not clearly cover the period through the next major DME data readout. Unless additional savings, financing, or business development proceeds are secured, funding needs could arise before pivotal results clarify the program’s commercial and regulatory prospects.

EyePoint Pharmaceuticals News

PV3B FAQ

What was EyePoint Pharmaceuticals’s price range in the past 12 months?
EyePoint Pharmaceuticals lowest stock price was €0.25 and its highest was €16.13 in the past 12 months.
What is EyePoint Pharmaceuticals’s market cap?
EyePoint Pharmaceuticals’s market cap is €28.21M.
When is EyePoint Pharmaceuticals’s upcoming earnings report date?
EyePoint Pharmaceuticals’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 105 days.
How were EyePoint Pharmaceuticals’s earnings last quarter?
EyePoint Pharmaceuticals released its earnings results on Nov 12, 2026. The company reported -€0.975 earnings per share for the quarter, missing the consensus estimate of -€0.848 by -€0.128.
Is EyePoint Pharmaceuticals overvalued?
According to Wall Street analysts EyePoint Pharmaceuticals’s price is currently Undervalued.
Does EyePoint Pharmaceuticals pay dividends?
EyePoint Pharmaceuticals does not currently pay dividends.
What is EyePoint Pharmaceuticals’s EPS estimate?
EyePoint Pharmaceuticals’s EPS estimate is -0.63.
How many shares outstanding does EyePoint Pharmaceuticals have?
EyePoint Pharmaceuticals has 113,782,600 shares outstanding.
What happened to EyePoint Pharmaceuticals’s price movement after its last earnings report?
EyePoint Pharmaceuticals reported an EPS of -€0.975 in its last earnings report, missing expectations of -€0.848. Following the earnings report the stock price went down -8.537%.
Which hedge fund is a major shareholder of EyePoint Pharmaceuticals?
Hedge funds hold EyePoint Pharmaceuticals shares: the largest hedge-fund position in EyePoint Pharmaceuticals is 1,083,195,037 shares, and hedge funds increased their holdings by 200.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology